EGFR and non-small cell lung carcinoma: In 2011, the American Society of Clinical Oncology advanced clinical guidelines recommending the use of EGFR mutation testing in non-small cell lung cancer (NSCLC) patients in order to consider EGFR tyrosine kinase inhibitors as first line therapy [27].